An2 Therapeutics Inc. has received a research grant from the Bill & Melinda Gates Foundation to discover novel, boron-containing small molecules for the treatment of tuberculosis (TB) and malaria.
Methicillin-resistant S. aureus (MRSA) causes difficult-to-treat infections due to its inherent resistance. Thus finding new strategies to overcome MRSA resistance is critical. Researchers from China Agricultural University reported on the discovery and optimization of a novel series of pleuromutilin derivatives containing benzoxazole-2-thiol.
TANK-binding kinase 1 (TBK1) serves prominent innate immune functions via complex interactions with adaptor proteins to affect phosphorylation of NF-κB (NF-κB). TBK1 is at the nexus of multiple pathways connecting interferon pathway activation and this is ultimately beneficial or hyperinflammatory-pathological in the context of viral infections.
Westvac Biopharma Co. Ltd. has described keto amide derivatives acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Via Nova Therapeutics Inc. has received clearance of its IND application from the FDA for its influenza A nucleoprotein inhibitor, VNT-101. The novel investigational small molecule is directed against a novel target, the influenza A nucleoprotein, and is being developed for treatment of seasonal influenza A infection.
Researchers at Ningbo Combireg Pharmaceutical Technology Co. Ltd. and Versitech Ltd. have described benzothiazole compounds reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have disclosed zwitterionic compounds reported to be useful for the treatment of bacterial infections.
Transimmune AG has been awarded a $5 million investment from the Bill & Melinda Gates Strategic Investment Fund that will be used to leverage Transimmune’s physiologically induced dendritic cells (phDCs) to enhance the potency of mRNA vaccines in infectious diseases. The initial focus will be on a therapeutic vaccine for people with HIV.
RSS
